Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4338

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 4,338 matching trials for Lung Cancer.

Live ClinicalTrials.gov results.

Active filters: "small cell lung cancer" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Melanoma, Li-Fraumeni Syndrome, Pulmonary Blastoma, Chordoma, Congenital Bone Marrow Failure Syndromes, Costello Syndrome, Fanconi Anemia, CFC Syndrome (CFCS), Legius Syndrome, RASopathies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Recurrent or Refractory, Solid Tumors
Interventions: Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: New Haven, Connecticut • Ocala, Florida • Tampa, Florida + 7 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: sigvotatug vedotin, docetaxel; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 130
States / cities: Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more

Conditions: Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Lung Cancer, Non-squamous, Non-small Cell
Interventions: zongertinib, pembrolizumab, cisplatin, carboplatin, pemetrexed; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 22
States / cities: Huntsville, Alabama • Bullhead City, Arizona • Beverly Hills, California + 19 more

Conditions: Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, Lung Cancer NOS, Thoracic Cancers, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 1,559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Sotorasib, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 23
States / cities: Santa Barbara, California • Newark, Delaware • Chicago, Illinois + 18 more

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 15
States / cities: Newark, Delaware • Coeur d'Alene, Idaho • Post Falls, Idaho + 9 more

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Clinical Genetics Branch Eligibility Screening Survey

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

About this Lung Cancer clinical trials directory page